💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 10% YoY in FY24 to INR 48,560 Cr and 8.6% YoY in Q2 FY26 to INR 14,405.2 Cr. Domestic formulations, the largest segment, contributed 33% of revenue in H1 FY25. The global specialty business grew to represent 18% of FY24 revenue and approximately 20% of total sales by Q2 FY26. Emerging Markets revenue grew 9.2% YoY to INR 9,416 Cr in FY25, while the US business saw a 4.1% decline to $496 million in Q2 FY26 due to generic pricing pressures.

Geographic Revenue Split

India formulations account for 33% of total revenue as of H1 FY25. The US market is a significant contributor, though it faced a 4.1% quarterly decline to $496 million in Q2 FY26. Emerging Markets (including Bangladesh, South Africa, and Russia) contributed INR 9,416 Cr in FY25, representing a 9.2% YoY growth. The 'Rest of World' markets (excluding India and US) are also expanding, though Japan faced moderate growth due to pricing pressures.

Profitability Margins

Adjusted Profit After Tax (APAT) margin was 19.5% in FY24 (INR 9,457 Cr) compared to 18.3% in FY23. Gross margin stood at 79.3% in Q2 FY26. Net profit for Q2 FY26 was INR 3,118 Cr, up 2.6% YoY. Margins are supported by the increasing mix of high-margin specialty products but are partially offset by R&D investments of 7-8% of revenue and high marketing expenses for new launches.

EBITDA Margin

EBITDA margin improved to 31.3% in Q2 FY26 compared to 29.6% in Q2 FY25, driven by a higher contribution from specialty medicines and operational efficiencies. Absolute EBITDA for Q2 FY26 was INR 4,527.1 Cr, registering a 14.9% YoY increase.

Capital Expenditure

The company has approved a major greenfield investment of INR 3,000 Cr for a formulations manufacturing facility in Madhya Pradesh. Annual organic maintenance capex is expected to remain moderate at $200-250 million (approx. INR 1,600-2,100 Cr), funded entirely through internal cash accruals.

Credit Rating & Borrowing

The company maintains a 'Stable' outlook from CRISIL Ratings. Debt reduced to INR 2,081 Cr as of September 30, 2024, from INR 2,846 Cr in March 2024. Interest coverage is exceptionally strong at 60.99 times, and the company holds a net cash surplus exceeding INR 25,000 Cr ($2.9 billion) as of Q2 FY26.

⚙️ Operational Drivers

Raw Materials

Bulk drugs (APIs) and formulations are the primary raw material components, with bulk drugs accounting for approximately 5% of total revenue. Specific chemical names are not disclosed.

Import Sources

Not specifically disclosed, though the company operates manufacturing facilities in India, Bangladesh, South Africa, Malaysia, Romania, Egypt, Morocco, Nigeria, and Russia to support local supply chains.

Capacity Expansion

Current expansion includes a new INR 3,000 Cr greenfield formulations facility in Madhya Pradesh. The company also recently acquired all outstanding shares of Taro Pharmaceutical Industries Ltd for INR 2,902 Cr to consolidate its global generics footprint.

Raw Material Costs

Raw material costs are managed through vertical integration, particularly in the specialty and generic segments. While specific YoY cost changes for raw materials are not detailed, the gross margin of 79.3% suggests high value-add over base material costs.

Manufacturing Efficiency

The company focuses on vertical integration to ensure supply chain reliability. Efficiency is also driven by a dedicated sales force of over 2,900 representatives in emerging markets to maximize brand adoption.

Logistics & Distribution

The company utilizes a dedicated sales force and local manufacturing in key regions like Romania and Nigeria to reduce distribution lead times and manage costs.

📈 Strategic Growth

Expected Growth Rate

7-9%

Growth Strategy

Growth will be achieved through the ramp-up of the global specialty portfolio (currently 20% of sales), new product launches in India (9 launched in Q2 FY26), and the INR 3,000 Cr greenfield expansion in Madhya Pradesh. Strategic acquisitions like Taro and Checkpoint, along with alliances like the AstraZeneca partnership for Hyperkalaemia, are key to expanding market reach.

Products & Services

Specialty and generic medicines in dermatology, ophthalmology, onco-dermatology, and chronic segments; bulk drugs (APIs); and consumer healthcare products.

Brand Portfolio

Sun Pharma, Taro, Checkpoint, and various chronic segment formulation brands.

New Products/Services

Launched 9 new products in India in Q2 FY26. The specialty portfolio, including innovative medicines, now accounts for 20% of total sales.

Market Expansion

Focusing on gaining critical mass in Emerging Markets and Western Europe. The company is expanding its specialty basket in these regions to move away from low-margin generics.

Market Share & Ranking

Ranked No. 1 in the Indian pharmaceutical market with an 8.1% market share as of September 2024.

Strategic Alliances

Partnered with AstraZeneca Pharma India Limited to distribute medicines for Hyperkalaemia in India.

🌍 External Factors

Industry Trends

The industry is shifting toward specialty and innovative medicines to counter generic pricing erosion. Sun Pharma is positioned as a leader in this shift, with specialty products growing to 20% of sales. The Indian market remains a high-growth area driven by chronic therapies.

Competitive Landscape

Faces intense competition in the US from authorized generics and customer consolidation. In India, it competes with local and international firms but maintains the top position in prescription volume.

Competitive Moat

The moat is built on a leadership position in the domestic chronic segment (8.1% share), a vertically integrated manufacturing model, and a growing portfolio of patented specialty products which are harder for competitors to replicate than standard generics.

Macro Economic Sensitivity

Highly sensitive to foreign exchange fluctuations; reported a forex gain of INR 430.5 Cr in Q2 FY26 compared to INR 128.1 Cr in the previous year.

Consumer Behavior

Demand is driven by healthcare professionals; Sun Pharma is the most prescribed company across 13 doctor categories, reflecting strong brand trust and medical representative reach.

Geopolitical Risks

Geopolitical tensions are cited as a primary risk to the global supply chain, potentially impacting manufacturing sites in regions like Russia and Egypt.

⚖️ Regulatory & Governance

Industry Regulations

Subject to stringent US FDA inspections. Current import alerts are active for facilities in Halol (Gujarat), Toansa (Punjab), Dewas (MP), and Poanta Sahib (HP), which restrict US supply.

Environmental Compliance

The company has reduced Scope 1 and 2 emissions by 22% and water consumption by 31% as of FY24 against a 2020 baseline. 45% of energy is sourced from renewables.

Taxation Policy Impact

Effective Tax Rate (ETR) was 24.7% in Q2 FY26, up from 15.8% in Q2 FY25.

Legal Contingencies

Settled the GxMDL putative class action case for INR 1,711.2 Cr. Other ongoing litigations and disputed tax liabilities exist, though the impact is not fully ascertainable.

⚠️ Risk Analysis

Key Uncertainties

Regulatory outcomes from the US FDA remain the primary uncertainty; adverse observations can lead to significant revenue loss (e.g., Halol's 3% impact). Litigation payouts, like the INR 1,711.2 Cr settlement, also impact liquidity.

Geographic Concentration Risk

High concentration in India (33% of revenue) and the US market. Any regulatory or policy change in these two regions significantly impacts the financial profile.

Third Party Dependencies

Not disclosed, but vertical integration in APIs reduces dependency on external suppliers for key products.

Technology Obsolescence Risk

The company manages technology risks through an ERM framework and focuses on upskilling its workforce (92% male, 8% female) to handle complex manufacturing processes.

Credit & Counterparty Risk

Credit risk is low given the 'Superior' liquidity rating and net cash position of over INR 25,000 Cr.